| List | Section | Observation |
|---|---|---|
| WHO Model List of Essential Medicines (2021) | 6.4.2.1. Nucleoside/Nucleotide reverse transcriptase inhibitors | No observations |
| List | Section | Observation |
|---|---|---|
| WHO Model List of Essential Medicines (2021) | 6.4.2.1. Nucleoside/Nucleotide reverse transcriptase inhibitors | No observations |
| PAHO Strategic Fund Medicine List | 2.6.1. Antiretrovirals |
Others observations: 100 mL |
| Peru | 6.4.2.1 Nucleoside Reverse Transcriptase Inhibitors | No observations |
| List | Section | Observation |
|---|---|---|
| WHO Model List of Essential Medicines (2021) | 6.4.2.1. Nucleoside/Nucleotide reverse transcriptase inhibitors | No observations |
| PAHO Strategic Fund Medicine List | 2.6.1. Antiretrovirals | No observations |
| Chile | Essential and Prioritized Medications | No observations |
| List | Section | Observation |
|---|---|---|
| WHO Model List of Essential Medicines (2021) | 6.4.2.1. Nucleoside/Nucleotide reverse transcriptase inhibitors | No observations |
| PAHO Strategic Fund Medicine List | 2.6.1. Antiretrovirals | No observations |
| Bolivia | LINAME 2011 - 2013 | No observations |
| Peru | 6.4.2.1 Nucleoside Reverse Transcriptase Inhibitors | No observations |
| Chile | Essential and Prioritized Medications | No observations |
| Colombia | 2.0 AIDS | No observations |
| Cuba | 6.4 Antivirales | No observations |
| List | Section | Observation |
|---|---|---|
| Peru | 6.4.2.1 Nucleoside Reverse Transcriptase Inhibitors | No observations |